Antibiotics Need Additional Development Incentives, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
CDER Director Woodcock tells House panel that a guidance clarifying trial designs is not enough, an acknowledgement a Cubist executive calls a "break-through."